
Corcept’s Phase III trial of ovarian cancer therapy shows PFS improvement
Corcept Therapeutics’ pivotal Phase III ROSELLA trial of oral relacorilant in combination with nab-paclitaxel has met its primary endpoint, demonstrating an improvement in progression-free survival (PFS) in individuals with platinum-resistant ovarian …